Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease

doi:10.1111/j.1651-2227.2007.00042.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Systems Maintenance, Monday, 15th February 2010

Wiley InterScience

Acta Pædiatrica

Volume 96 Issue 1, Pages 128 - 130

Published Online: 7 Dec 2006

Published on behalf of

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 128K) | Related Articles | Citation Tracking

SHORT COMMUNICATIONS

Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease

K-L Kolho ( kaija-leena.kolho@helsinki.fi ¹ ), T Ruuska ² , E Savilahti ¹

1.Hospital for Children and Adolescents, University of Helsinki, Box 281, FIN-00029 HYKS, Helsinki, Finland 2.Department of Pediatrics, Tampere University Hospital, Box 2000, FIN-33014, Tampere, Finland

Correspondence
K-L Kolho, Hospital for Children and Adolescents, Box 281, FIN-00029, Finland. Tel: +358-9-471 74787 | Fax: +358-9-471 72599 | Email: kaija-leena.kolho@helsinki.fi

KEYWORDS

Adverse effect • Crohn´s disease • TNF-alpha antagonist • Ulcerative colitis

ABSTRACT

Since 2000 we have introduced 141 Infliximab infusions to 23 children with severe inflammatory bowel disease. A total of seven severe adverse reactions occurred in 26% (6 of 23) of the children. Four reactions were acute (anaphylaxis n = 2; allergic reaction n = 2) and 3/4 of these children were younger than 10 years of age. Two children developed an abscess and one child had septicaemia and brain lesions related to progressive multifocal leucoencephalopathy.

Conclusion: adverse reactions to Infliximab infusions are common. Young children seem to be prone to severe allergic reactions although they are on azathioprine and conventional glucocorticoid therapy.

Received
15 May 2006; revised 30 June 2006; accepted 11 July 2006

DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1651-2227.2007.00042.x About DOI